Polymorphic drug metabolizing enzymes and drug transporters affect the pharmacokinetics of drugs whereas polymorphic drug targets and disease related pathways influence the pharmacodynamic action of drugs [Samer et al, 2006]. Prospective trials are urgently needed to study the inherited susceptibility that may lead to a lack of therapeutic analgesic efficacy, or dose-dependent induced adverse drug reactions.